cholestyramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
727 11041-12-6

Description:

MoleculeDescription

Synonyms:

  • colestyramine
  • cholestyramine
  • cholestyramine chloride
  • colestyramin
  • Molecular weight: 1162
  • Formula: C68H97Cl5N5
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
14 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Aug. 3, 1973 FDA BRISTOL MYERS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 187.94 13.00 453 13448 714913 62760208
Product taste abnormal 92.13 13.00 29 13872 2038 63473083
Frequent bowel movements 91.29 13.00 59 13842 22963 63452158
Product physical consistency issue 77.62 13.00 20 13881 679 63474442
Product solubility abnormal 64.49 13.00 18 13883 832 63474289
Product residue present 56.47 13.00 24 13877 3955 63471166
Colitis 51.14 13.00 58 13843 48470 63426651
Laparotomy 43.29 13.00 11 13890 353 63474768
Abdominal pain 40.84 13.00 149 13752 293307 63181814
Intestinal anastomosis 40.66 13.00 11 13890 452 63474669
Bulimia nervosa 40.41 13.00 11 13890 463 63474658
Bowel movement irregularity 35.41 13.00 19 13882 5245 63469876
Toxicity to various agents 35.02 13.00 6 13895 247244 63227877
Faecal calprotectin increased 34.75 13.00 16 13885 3187 63471934
Contraindicated product administered 33.81 13.00 4 13897 217644 63257477
Gastrointestinal wall thickening 32.29 13.00 12 13889 1392 63473729
Cholangitis sclerosing 30.47 13.00 12 13889 1629 63473492
Clostridium difficile infection 30.23 13.00 35 13866 29887 63445234
Intestinal fibrosis 30.12 13.00 7 13894 153 63474968
Bile acid malabsorption 29.18 13.00 7 13894 176 63474945
Product use complaint 28.86 13.00 13 13888 2461 63472660
Glossodynia 28.51 13.00 3 13898 178873 63296248
Rheumatoid arthritis 28.50 13.00 10 13891 253809 63221312
Sacroiliitis 28.40 13.00 14 13887 3243 63471878
Intestinal resection 27.11 13.00 13 13888 2835 63472286
Ileal stenosis 26.54 13.00 11 13890 1702 63473419
Abdominal distension 25.86 13.00 58 13843 86557 63388564
Systemic lupus erythematosus 25.66 13.00 7 13894 208911 63266210
Cerebral venous sinus thrombosis 25.05 13.00 11 13890 1961 63473160
Ophthalmoplegia 24.73 13.00 10 13891 1454 63473667
Intestinal obstruction 24.51 13.00 32 13869 30867 63444254
Mesenteric vein thrombosis 23.75 13.00 9 13892 1101 63474020
Terminal ileitis 23.30 13.00 8 13893 738 63474383
Wound 23.02 13.00 4 13897 163259 63311862
Blood alkaline phosphatase increased 21.75 13.00 36 13865 42931 63432190
Small intestinal obstruction 21.17 13.00 23 13878 18314 63456807
Post procedural diarrhoea 21.06 13.00 7 13894 585 63474536
Therapeutic product effect decreased 21.02 13.00 8 13893 193179 63281942
Foreign body in throat 20.59 13.00 6 13895 324 63474797
Suprapubic pain 20.52 13.00 7 13894 633 63474488
Serum ferritin increased 20.07 13.00 14 13887 6168 63468953
Retching 19.83 13.00 20 13881 14625 63460496
Nephrolithiasis 19.69 13.00 34 13867 41950 63433171
Colectomy 19.21 13.00 10 13891 2596 63472525
Product odour abnormal 19.00 13.00 8 13893 1288 63473833
Flatulence 18.82 13.00 30 13871 34672 63440449
Pleural rub 18.45 13.00 4 13897 63 63475058
Intestinal stenosis 18.26 13.00 10 13891 2874 63472247
Crohn's disease 18.02 13.00 12 13889 4901 63470220
Proctalgia 17.90 13.00 13 13888 6097 63469024
Cystitis 17.74 13.00 38 13863 54953 63420168
Weight decreased 17.48 13.00 112 13789 276686 63198435
Intestinal anastomosis complication 17.40 13.00 5 13896 257 63474864
Sarcoma 16.99 13.00 6 13895 601 63474520
Drug level decreased 16.98 13.00 14 13887 7905 63467216
Cholecystitis infective 16.91 13.00 8 13893 1694 63473427
Remission not achieved 15.78 13.00 4 13897 127 63474994
Laboratory test abnormal 15.61 13.00 24 13877 26888 63448233
Alanine aminotransferase increased 15.50 13.00 54 13847 103716 63371405
Enterocutaneous fistula 15.22 13.00 7 13894 1390 63473731
Rash macular 15.22 13.00 22 13879 23342 63451779
Ileostomy 14.83 13.00 7 13894 1475 63473646
Gastrointestinal bacterial overgrowth 14.81 13.00 6 13895 876 63474245
Gastroenteritis 14.43 13.00 23 13878 26567 63448554
Muscle spasms 14.40 13.00 70 13831 156080 63319041
Aspartate aminotransferase increased 14.38 13.00 48 13853 90229 63384892
Red blood cell abnormality 14.33 13.00 5 13896 484 63474637
Short-bowel syndrome 14.14 13.00 5 13896 503 63474618
Jaundice 14.12 13.00 24 13877 29227 63445894
Klebsiella infection 14.05 13.00 13 13888 8553 63466568
Cholelithiasis 13.76 13.00 30 13871 43895 63431226
Ovarian cyst 13.41 13.00 17 13884 15928 63459193
Thyroidectomy 13.28 13.00 6 13895 1144 63473977
Drug intolerance 13.27 13.00 30 13871 308631 63166490
Benign vulval neoplasm 13.21 13.00 3 13898 59 63475062
General symptom 13.14 13.00 8 13893 2800 63472321

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 80.79 17.04 223 7268 389689 34559751
Alveolar lung disease 73.64 17.04 17 7474 369 34949071
Pulmonary interstitial emphysema syndrome 68.47 17.04 17 7474 507 34948933
Diffuse alveolar damage 47.17 17.04 18 7473 2296 34947144
Intestinal intraepithelial lymphocytes increased 40.63 17.04 9 7482 161 34949279
Intestinal obstruction 38.83 17.04 35 7456 22787 34926653
Nerve degeneration 38.82 17.04 9 7482 199 34949241
Cryptitis 37.69 17.04 9 7482 227 34949213
Eosinophilic pneumonia 36.82 17.04 17 7474 3484 34945956
Faecal calprotectin increased 35.28 17.04 15 7476 2529 34946911
Product taste abnormal 34.64 17.04 12 7479 1162 34948278
Microvillous inclusion disease 33.88 17.04 8 7483 192 34949248
Apoptosis 32.74 17.04 9 7482 402 34949038
Probiotic therapy 31.20 17.04 7 7484 133 34949307
Hemivertebra 30.31 17.04 7 7484 152 34949288
Abdominal rigidity 29.26 17.04 11 7480 1346 34948094
Hepatic enzyme abnormal 27.75 17.04 13 7478 2753 34946687
Hyperammonaemia 27.26 17.04 17 7474 6350 34943090
Transaminases abnormal 26.68 17.04 7 7484 261 34949179
Biopsy 25.61 17.04 7 7484 306 34949134
Bacterial diarrhoea 24.59 17.04 5 7486 58 34949382
Small intestinal obstruction 23.72 17.04 22 7469 14844 34934596
Colitis microscopic 23.49 17.04 11 7480 2326 34947114
Renal mass 22.92 17.04 10 7481 1794 34947646
Vascular device infection 22.67 17.04 13 7478 4172 34945268
Renal neoplasm 22.58 17.04 9 7482 1288 34948152
Dehydration 22.48 17.04 70 7421 129899 34819541
Oesophageal atresia 22.19 17.04 7 7484 506 34948934
Hepatic encephalopathy 22.03 17.04 21 7470 14664 34934776
Enterocolonic fistula 22.00 17.04 5 7486 101 34949339
Inappropriate schedule of product administration 21.89 17.04 44 7447 62252 34887188
Erosive duodenitis 20.11 17.04 9 7482 1715 34947725
Drug ineffective 19.89 17.04 166 7325 456585 34492855
Escherichia urinary tract infection 19.16 17.04 11 7480 3535 34945905
Bone density decreased 19.14 17.04 9 7482 1920 34947520
Generalised oedema 19.10 17.04 18 7473 12390 34937050
Arthralgia 18.69 17.04 79 7412 169962 34779478
Frequent bowel movements 18.64 17.04 18 7473 12769 34936671
Rectal haemorrhage 18.62 17.04 32 7459 40217 34909223
Glomerular filtration rate decreased 18.43 17.04 18 7473 12943 34936497
Eczema 18.05 17.04 21 7470 18415 34931025
Product solubility abnormal 18.04 17.04 6 7485 513 34948927
Abdominal adhesions 17.97 17.04 8 7483 1505 34947935
Poor venous access 17.68 17.04 12 7479 5171 34944269
Eye haemorrhage 17.19 17.04 11 7480 4294 34945146
Myalgia 17.10 17.04 48 7443 84062 34865378

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 131.21 13.34 432 15680 880057 78848219
Pulmonary interstitial emphysema syndrome 69.49 13.34 17 16095 506 79727770
Alveolar lung disease 67.83 13.34 17 16095 560 79727716
Faecal calprotectin increased 63.28 13.34 28 16084 5513 79722763
Frequent bowel movements 58.09 13.34 48 16064 29491 79698785
Product solubility abnormal 50.24 13.34 15 16097 957 79727319
Intestinal obstruction 49.77 13.34 52 16060 42968 79685308
Product physical consistency issue 46.92 13.34 14 16098 891 79727385
Abdominal pain 43.02 13.34 174 15938 389395 79338881
Intestinal resection 42.95 13.34 19 16093 3738 79724538
Toxicity to various agents 42.57 13.34 16 16096 421524 79306752
Small intestinal obstruction 40.92 13.34 38 16074 27234 79701042
Intestinal intraepithelial lymphocytes increased 40.64 13.34 9 16103 171 79728105
Diffuse alveolar damage 40.47 13.34 18 16094 3586 79724690
Vascular device infection 36.83 13.34 24 16088 10252 79718024
Nerve degeneration 36.34 13.34 9 16103 282 79727994
Bowel movement irregularity 36.27 13.34 20 16092 6314 79721962
Cryptitis 36.13 13.34 9 16103 289 79727987
Eosinophilic pneumonia 33.84 13.34 18 16094 5292 79722984
Microvillous inclusion disease 33.41 13.34 8 16104 217 79728059
Product residue present 31.39 13.34 15 16097 3521 79724755
Apoptosis 31.16 13.34 9 16103 511 79727765
Product taste abnormal 30.94 13.34 13 16099 2258 79726018
Probiotic therapy 30.68 13.34 7 16105 153 79728123
Intestinal anastomosis 28.71 13.34 9 16103 676 79727600
Laparotomy 28.22 13.34 8 16104 425 79727851
Completed suicide 27.11 13.34 8 16104 245759 79482517
Product use complaint 26.60 13.34 12 16100 2471 79725805
Cholangitis sclerosing 25.91 13.34 12 16100 2625 79725651
Clostridium difficile infection 25.53 13.34 37 16075 42648 79685628
Abdominal adhesions 25.31 13.34 13 16099 3560 79724716
Enterocolonic fistula 25.23 13.34 6 16106 158 79728118
Dehydration 25.11 13.34 108 16004 248079 79480197
Abdominal distension 24.52 13.34 66 16046 119584 79608692
Colitis 24.47 13.34 49 16063 73258 79655018
Hepatic encephalopathy 24.07 13.34 27 16085 24139 79704137
Off label use 23.53 13.34 283 15829 906932 78821344
Bile acid malabsorption 23.50 13.34 6 16106 213 79728063
Colectomy 23.10 13.34 12 16100 3362 79724914
Inappropriate schedule of product administration 22.80 13.34 69 16043 133559 79594717
Terminal ileitis 22.31 13.34 8 16104 909 79727367
Intestinal stenosis 21.90 13.34 12 16100 3742 79724534
Cerebrovascular accident 21.79 13.34 75 16037 155217 79573059
Blood pressure increased 21.39 13.34 92 16020 211268 79517008
Abdominal rigidity 21.19 13.34 11 16101 3077 79725199
Poor venous access 21.10 13.34 22 16090 18127 79710149
Mesenteric vein thrombosis 20.12 13.34 9 16103 1818 79726458
Biopsy 19.95 13.34 7 16105 747 79727529
Therapeutic reaction time decreased 19.90 13.34 11 16101 3490 79724786
Gastrointestinal wall thickening 19.79 13.34 10 16102 2647 79725629
Hyperammonaemia 19.69 13.34 17 16095 11076 79717200
Product odour abnormal 19.34 13.34 8 16104 1336 79726940
Renal neoplasm 19.30 13.34 9 16103 1999 79726277
Bacterial diarrhoea 19.23 13.34 5 16107 191 79728085
Transaminases abnormal 19.03 13.34 7 16105 855 79727421
Ophthalmoplegia 18.92 13.34 10 16102 2902 79725374
Foreign body in throat 18.86 13.34 6 16106 473 79727803
Erosive duodenitis 18.85 13.34 9 16103 2108 79726168
Pleural rub 18.59 13.34 4 16108 66 79728210
Anal fissure 18.32 13.34 14 16098 7689 79720587
Blood alkaline phosphatase increased 18.27 13.34 40 16072 63624 79664652
Nephrolithiasis 18.24 13.34 36 16076 53255 79675021
Rheumatoid arthritis 17.77 13.34 10 16102 208460 79519816
Renal mass 17.64 13.34 10 16102 3330 79724946
Enteritis 17.53 13.34 18 16094 14565 79713711
Myopathy 17.19 13.34 21 16091 20542 79707734
Hernia 16.89 13.34 19 16093 17040 79711236
Arthralgia 16.84 13.34 183 15929 571620 79156656
Rectal haemorrhage 16.55 13.34 43 16069 76257 79652019
Contraindicated product administered 15.84 13.34 6 16106 157532 79570744
Metastasis 15.26 13.34 12 16100 6868 79721408
Proctalgia 15.12 13.34 14 16098 9987 79718289
Drug interaction 15.08 13.34 39 16073 415144 79313132
Sarcoma 14.93 13.34 6 16106 930 79727346
Jaundice 14.72 13.34 33 16079 53316 79674960
Muscle spasms 14.66 13.34 72 16040 174658 79553618
Lymphocyte count increased 14.59 13.34 11 16101 5921 79722355
Myalgia 14.52 13.34 75 16037 185566 79542710
Ileostomy 14.37 13.34 7 16105 1713 79726563
Weight decreased 14.05 13.34 121 15991 355077 79373199
Gastric polyps 14.04 13.34 9 16103 3738 79724538
Colitis ulcerative 13.78 13.34 25 16087 34717 79693559
Heart rate decreased 13.61 13.34 38 16074 70278 79657998
Incorrect dose administered 13.47 13.34 40 16072 76590 79651686
Benign vulval neoplasm 13.45 13.34 3 16109 59 79728217
Serum ferritin increased 13.40 13.34 13 16099 9834 79718442
Drug ineffective for unapproved indication 13.37 13.34 31 16081 51207 79677069
Pruritus 13.36 13.34 130 15982 394518 79333758

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C10AC01 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Bile acid sequestrants
FDA MoA N0000175365 Bile-acid Binding Activity
FDA EPC N0000180292 Bile Acid Sequestrant

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Hyperlipidemia indication 55822004 DOID:1168
Biliary Obstruction with Pruritus indication
Poisoning by digitalis glycoside off-label use 12876009
Chronic diarrhea off-label use 236071009
Classical phenylketonuria contraindication 7573000
Constipation contraindication 14760008 DOID:2089
Hypovolemia contraindication 28560003
Blood coagulation disorder contraindication 64779008 DOID:1247
Hemorrhoids contraindication 70153002 DOID:9746
Kidney disease contraindication 90708001 DOID:557
Calculus in biliary tract contraindication 266474003
Complete Biliary Obstruction contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018811 VUID
N0000147114 NUI
D02690 KEGG_DRUG
2447 RXNORM
4018811 VANDF
CHEMBL1201625 ChEMBL_ID
1005 INN_ID
DB01432 DRUGBANK_ID
4B33BGI082 UNII
4435 MMSL
6264 MMSL
d00193 MMSL
001216 NDDF
387408001 SNOMEDCT_US
72824008 SNOMEDCT_US
C0008402 UMLSCUI
137699107 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
cholestyramine light HUMAN PRESCRIPTION DRUG LABEL 1 0185-0939 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
cholestyramine light HUMAN PRESCRIPTION DRUG LABEL 1 0185-0939 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 0185-0940 POWDER, FOR SUSPENSION 4 g ORAL ANDA 19 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 0185-0940 POWDER, FOR SUSPENSION 4 g ORAL ANDA 19 sections
Prevalite HUMAN PRESCRIPTION DRUG LABEL 1 0245-0036 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 0245-0536 POWDER, FOR SUSPENSION 4 g ORAL ANDA 19 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 0832-0536 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 0832-0536 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 24658-266 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE LIGHT HUMAN PRESCRIPTION DRUG LABEL 1 24658-270 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
CHOLESTYRAMINE LIGHT HUMAN PRESCRIPTION DRUG LABEL 1 24658-271 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
Cholestyramine Human Prescription Drug Label 1 27241-134 POWDER, FOR SUSPENSION 4 g ORAL ANDA 20 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 42806-265 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 42806-266 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 42806-267 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE LIGHT HUMAN PRESCRIPTION DRUG LABEL 1 42806-269 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
CHOLESTYRAMINE LIGHT HUMAN PRESCRIPTION DRUG LABEL 1 42806-270 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
CHOLESTYRAMINE LIGHT HUMAN PRESCRIPTION DRUG LABEL 1 42806-271 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 49884-465 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 49884-465 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 49884-466 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 49884-466 POWDER, FOR SUSPENSION 4 g ORAL ANDA 22 sections
QUESTRAN HUMAN PRESCRIPTION DRUG LABEL 1 49884-936 POWDER, FOR SUSPENSION 4 g ORAL ANDA 23 sections
QUESTRAN HUMAN PRESCRIPTION DRUG LABEL 1 49884-937 POWDER, FOR SUSPENSION 4 g ORAL ANDA 23 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 50090-3415 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
CHOLESTYRAMINE HUMAN PRESCRIPTION DRUG LABEL 1 50090-3845 POWDER, FOR SUSPENSION 4 g ORAL ANDA 12 sections
Cholestyramine Light HUMAN PRESCRIPTION DRUG LABEL 1 51224-009 POWDER, FOR SUSPENSION 4 g ORAL ANDA 23 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 51224-011 POWDER, FOR SUSPENSION 4 g ORAL ANDA 21 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 54868-4812 POWDER, FOR SUSPENSION 4 g ORAL ANDA 14 sections
Cholestyramine HUMAN PRESCRIPTION DRUG LABEL 1 54868-5526 POWDER, FOR SUSPENSION 4 g ORAL ANDA 14 sections